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Abnormal Bone Mineral Accrual in Adolescent Girls with
Anorexia Nervosa
LESLIE A. SOYKA, MADHUSMITA MISRA, APARNA FRENCHMAN, KAREN K. MILLER,
STEVEN GRINSPOON, DAVID A. SCHOENFELD, AND ANNE KLIBANSKI
Neuroendocrine Unit and General Clinical Research Center (M.M., A.F., K.K.M., S.G., D.A.S., A.K.), Massachusetts General
Hospital and Harvard Medical School, Boston, Massachusetts 02114; and Department of Pediatrics (L.A.S.), University of
Massachusetts Medical School, Worcester, Massachusetts 01655
Anorexia nervosa (AN) is increasingly common in adolescent
girls and occurs at a time of peak bone mass formation. Os-
teopenia is common in adolescent girls with AN, and in a
cross-sectional study, we have reported low bone formation
markers in such girls. To determine the impact of chronic
undernutrition on bone mineral accrual in contrast to healthy
controls, we prospectively measured bone mineral density
(BMD) and body composition by dual energy x-ray absorpti-
ometry, bone metabolism markers, and nutritional and hor-
monal status at baseline, 6 months, and 12 months in 19 ado-
lescent girls with AN (mean SEM, 15.40.4 yr) and 19 controls
of comparable chronological and skeletal age. Overall, nutri-
tional status in subjects with AN improved (mean percentage
increase in body mass index from baseline, 9.2  1.9% and
15.2  2.6% at 6 and 12 months, respectively), with 11 subjects
having recovered weight at 12 months. However, lumbar BMD
at 12 months (AN, 0.88  0.02 g/cm2, vs. control, 0.98  0.03
g/cm2; P  0.008) remained significantly reduced in AN com-
pared with controls, even in recovered subjects. This was due
to significant increases in lumbar BMD in controls vs. no
change in AN subjects over the year (0.003 0.001 g/cm2month
vs. 0.000 0.001 g/cm2month, respectively; P 0.04). The most
significant determinant of change in lumbar BMD at 12
months was change in lean body mass in both AN (r 0.62; P
0.008) and control (r  0.80; P  0.0006) groups. There were
significant increases in surrogate markers of bone turnover in
subjects with AN compared with controls as assessed by os-
teocalcin (AN, 0.9  0.4 g/litermonth, vs. control, 1.1  0.4
g/litermonth; P  0.0007), bone-specific alkaline phospha-
tase (AN, 0.6  0.5 U/litermonth, vs. control, 1.5  0.4
U/litermonth; P  0.002), deoxypyridinoline [AN, 0.1  0.1
nmol/mmol creatinine (cr) month, vs. control,0.4 0.1 nmol/
mmol crmonth; P  0.005], and N-telopeptide (AN, 4  4 nmol
BCE/mmol cr/month, vs. control, 9  4 nmol BCE/mmol cr/
month; P  0.01). Changes in IGF-I levels over the year were
highly correlated with changes in bone turnover over the
same period in AN (osteocalcin, r  0.77; P  0.001; deoxypyr-
idinoline, r  0.66; P  0.01). A rise in N-telopeptide over the
year was correlated with an increase in all bone mineral mea-
sures, including lumbar bone mineral content (r  0.58; P 
0.03) and BMD (r  0.53; P  0.05) and total bone mineral
content (r  0.69; P  0.006) and BMD (r  0.69; P  0.006) in
the AN group.
Therefore, despite recovery over 1 yr, poor bone mineral
accrual persists in adolescent girls with AN in contrast to
rapid bone accrual in healthy girls. Normalization of bone
turnover markers occurs in association with nutritional re-
covery and an increase in the nutritionally dependent bone
trophic factor IGF-I. A rise in bone turnover markers may be
an early indicator of increase in BMD in recovering girls with
AN. (J Clin Endocrinol Metab 87: 4177–4185, 2002)
OSTEOPENIA OCCURS IN approximately 50% of ado-lescent girls with anorexia nervosa (AN), and the on-
set of disease occurs at a time of peak bone mass develop-
ment (1–4). Reduced bone mass is seen after a brief duration
of illness and may persist despite recovery (2, 4–6). Adult
women with AN have widespread osteopenia and osteopo-
rosis, presumably attributed to bone loss (7). However, adult
women with AN with disease onset in adolescence have
lower bone mass than those with adult-onset AN (8). Because
the majority of bone mineral is accrued during adolescence,
any process that interferes with normal bone mineral accre-
tion may lead to permanent deficits. It is unclear whether
catch up can occur in bone mineral density (BMD) in ado-
lescent girls with AN with recovery of weight. Previous
reports (2, 4–6) have not included prospective data regard-
ing change in BMD with recovery compared with controls of
the same chronological age (CA) and skeletal maturation.
We have previously reported low spinal BMD in teenage
girls with AN compared with CA- and bone age (BA)-
matched controls (3). In that study, a decrease in bone for-
mation markers [osteocalcin (OC) and bone-specific alkaline
phophatase (BSAP)] was observed, indicating that low bone
formation occurs in association with low BMD in girls with
AN. Moreover, the low bone formation markers in such girls
were significantly associated with serum levels of IGF-I, a
bone trophic hormone that is highly dependent on nutri-
tional status.
In this study, we hypothesized that reduced bone mineral
accrual occurs in girls with AN during puberty and persists
in association with chronic undernutrition. Therefore, we
prospectively examined 38 adolescent girls (19 AN and 19
control) to determine whether 1) low bone formation mark-
ers in adolescents with AN are associated with abnormal
bone mass accretion, 2) improvement in BMD and markers
of bone metabolism can be predicted by nutritional status,
Abbreviations: AN, Anorexia nervosa; BA, bone age; BMC, bone
mineral content; BMD, bone mineral density; BMI, body mass index; CA,
chronological age; cr, creatinine; BSAP, bone-specific alkaline
phophatase; DHEAS, dehydroepiandrosterone sulfate; DPD, deoxypyr-
idinoline; E2, estradiol; IGFBP-3, IGF binding protein-3; OC, osteocalcin;
NTX, N-telopeptide; RDA, recommended daily allowance; T, testoster-
one; TBBMC, total body BMC; TBBMD, total body BMD.
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including body composition and levels of IGF-I, and 3) re-
ductions in BMD and bone formation markers persist despite
recovery of weight and menstrual function.
Subjects and Methods
Subjects
We studied 38 Caucasian adolescent girls, 19 with AN and 19 healthy
controls. Fourteen of the AN and 12 of the controls participated in a
previously reported cross-sectional bone density study (3). The AN
patients were 12.9–17.8 yr of age at baseline. All met Diagnostic and
Statistical Manual IV criteria for AN with a mean duration since diag-
nosis of 14  3 months (range, 1–48 months). One patient had concom-
itant bulimia. Patients had either primary (failure of menarche by age 16
yr; n  1) or secondary (n  12; mean duration, 21  4 months; range,
6–36 months) amenorrhea or were premenarchal (n  6). Two patients
with secondary amenorrhea had taken estrogen previously (for 6–18
months), but not within 3 months of the study. Patients receiving hor-
monal or other medications known to affect bone metabolism were
excluded. A history of traumatic bone fracture was reported during
childhood or adolescence in 26% of AN patients, but none occurred
within 6 months of the study and none were nontraumatic. Subjects were
recruited through mass mailings to primary health care providers and
through collaboration with eating disorder programs in the greater
Boston area.
A control group of 19 healthy Caucasian female adolescents, ages
12.1–17.8 yr, was recruited from primary care providers and by adver-
tisement in community newspapers. All had a body mass index (BMI;
kg/m2) between the 25th and 95th percentiles for age, based on pub-
lished standard charts (9). Three control subjects, ages 12.1–13.1 yr, were
premenarchal. All postmenarchal adolescents menstruated regularly.
None of the controls had a history of an eating disorder. Potential control
subjects with a medical condition, or receiving hormonal or other med-
ications known to affect bone metabolism, were excluded. A history of
traumatic bone fracture during childhood or adolescence was reported
in 23% of control subjects, but none occurred within 6 months of the
study.
The study protocol was approved by the Massachusetts General
Hospital Subcommittee on Human Subjects, and informed consent was
obtained from all subjects and their parents.
Experimental protocol
All subjects were evaluated at a screening outpatient visit at the
General Clinical Research Center at Massachusetts General Hospital, at
which time eligibility for study participation was determined and in-
struction in collection of urine samples and completion of 4-d food
records given. This was followed by an outpatient baseline visit during
which study measurements were performed. After the baseline study
visit, all subjects were asked to return at 6 and 12 months for repeat
measurements. All menstruating subjects were studied during the fol-
licular phase of the menstrual cycle to control for the effects of cycle stage
on biochemical and hormonal measurements. A medical and menstrual
history and physical examination were performed at all visits. A 2-h,
second morning urine sample was collected before all visits. All blood
samples were drawn in the fasting state. Urine and serum samples were
obtained for biochemical and hormonal measurements as outlined be-
low. Bone density and body composition were assessed in all subjects
at each visit.
Methods
Anthropometric measurements. Subjects’ heights were measured using a
single stadiometer (average of triplicate measurements), and weights
were measured in a hospital gown on an electronic scale. BMI was
calculated, and BMI percentile was determined from published charts (9).
Classification of subjects by BA. All AN and control subjects had their BA
determined by x-ray of the left hand and wrist using the methods of
Greulich and Pyle (10). For the analysis of biochemical parameters that
are dependent on pubertal stage, such as gonadal steroids and markers
of bone formation and resorption, we analyzed groups according to
maturity. Because Tanner breast staging is difficult in girls with AN who
are hypoestrogenemic, we classified the maturational stage of subjects
by BA, subdividing the subjects into immature (BA 15 yr) and mature
(BA  15 yr) groups. We used the cut-off BA of 15 yr as mature in that
all epiphyses are near fusion and 99% of final adult height has been
attained (10).
Biochemical assessment. Serum-ionized calcium, phosphorus, TSH, and
urine creatinine were measured in the hospital laboratory using pub-
lished methods (11).
Serum estradiol (E2) was measured by ultra-sensitive RIA (Diagnostic
Systems Laboratories, Inc., Webster, TX). The detection limit of the E2
assay is 8.1 pmol/liter, and the coefficient of variation is 6.5–8.9%. Free
testosterone (T) was measured by RIA (DiaSorin, Inc., Stillwater, MN),
with a detection limit of 0.6 pmol/liter and an intra-assay coefficient of
variation of 3.7–6.2%. Serum dehydroepiandrosterone sulfate (DHEAS)
was measured by RIA (Coated Tube RIA, DiaSorin, Inc.) with a detection
limit of 0.03 mol/liter and an intra-assay coefficient of variation of
3.8–5.3%. Serum IGF-I was measured by an acid-alcohol extraction and
RIA kit (Nichols Institute Diagnostics, San Juan Capistrano, CA), with
a detection limit of 0.06 g/liter and an intra-assay coefficient of vari-
ation of 2.4–3.0%. Serum IGF binding protein-3 (IGFBP-3) was measured
using an immunoradiometric assay (Coated Tube IRMA, DiaSorin, Inc.)
with a detection limit of 0.5 g/liter and an intra-assay coefficient of
variation of 1.8–3.9%. Serum leptin was measured by RIA (Linco Re-
search, Inc., St. Charles, MO) with a sensitivity of 0.5 g/liter and an
intra-assay coefficient of variation of 3.4–8.3%. Serum OC was measured
using an immunoradiometric assay (Nichols Institute Diagnostics) with
a sensitivity of 0.5 g/liter and an intra-assay coefficient of variation of
3.2–5.2%. BSAP was measured by enzyme-linked immunoassay (Quidel,
Inc., Mountain View, CA) with a sensitivity of 0.7 U/liter and a coef-
ficient of variation of 3.9–5.8%. Urine deoxypyridinoline (DPD) and
N-telopeptide (NTX) were measured in a 2-h, second morning urine
sample normalized for creatinine excretion. DPD was measured by
enzyme-linked immunoassay (Quidel, Inc.) with a minimum detection
limit of 1.1 nmol/liter and an intra-assay coefficient of variation of
4.3–8.4%. NTX was measured by enzyme-linked immunoassay (Ostex
International, Inc., Seattle, WA) with a detection limit of 20 nmol BCE
and an intra-assay coefficient of variation of 5–19%. Serum was frozen
so that hormone determinations for each subject could be performed in
the same assay. All samples were run in duplicate.
Bone density and body composition. Total body and lumbar spine (L1-L4)
bone density was measured in the anteroposterior and lateral projections
by dual energy x-ray absorptiometry (QDR-4500, Hologic, Inc.,
Waltham, MA). The sd value for lumbar bone density measurement is
0.01 g/cm2 and does not vary with bone density. Whole body dual
energy x-ray absorptiometry was performed using a Hologic QDR-4500
densitometer to determine fat and lean body mass, which has been
validated in children and young adults (12, 13).
Nutrition and activity assessment. Calcium and vitamin D intake data were
obtained through computer analysis (Nutrition Data Systems, version 2,
Minneapolis, MN) of 4-d food records and history of dietary intake over
the month before the study visit. Typical exercise and activity of subjects
over the past year was determined using a validated questionnaire (14).
Statistical analysis
Longitudinal markers were measured at baseline, 6 months, and 12
months. A random slopes model (PROC MIXED in SAS) was used to
analyze these data. The model specifies that each patient has a random
intercept and slope, and the test for a group effect determines whether
the mean slope varies between groups. This method is similar to com-
paring the change from baseline in each group, however it can appro-
priately incorporate patients who were missing their 12-month follow-
up. T tests were used to compare baseline measures and percentage
change at 6 and 12 months.
Recovery from AN was defined as a 10% or greater increase in BMI
from baseline, regardless of resumption of menses.
Results
We studied 19 adolescent girls with AN and 19 healthy
controls. Baseline data on 14 of the AN and 12 of the control
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subjects has been previously published (3). All subjects were
evaluated at baseline and asked to return at 6 and 12 months.
All available data were collected and analyzed. Reasons for
not attending follow-up visits included hospitalization (AN,
n  4 visits) or loss of interest (AN, n  3; control, n  3
visits). Three control subjects were disqualified between the
6- and 12-month visits because they started taking oral con-
traceptive pills for birth control. Data were available for 14
AN and 18 control subjects at 6 months and for 17 AN and
14 controls at 12 months. Incomplete capture of subjects for
follow-up visits did not result in any differences in BA or
height between the groups at 6 and 12 months. Six AN
subjects at 6 months and 11 at 12 months were weight
recovered.
Clinical and anthropometric data
Clinical and anthropometric data for patients and controls
at baseline are summarized in Table 1. There were no sig-
nificant differences between patients and controls in BA, CA,
or height. BA/CA and weight were significantly lower in AN
patients compared with controls. Mean duration of AN was
14  3 months, and duration of amenorrhea in postmenar-
chal patients (n  12) was 21  4 months. All subjects were
Caucasian. No subjects regularly smoked cigarettes or con-
sumed alcohol.
Body composition data at each time point and rates of
change are summarized in Table 2. BMI, lean body mass, and
percentage body fat were significantly lower in AN at base-
line. In the AN group, nutritional status improved (percent-
age increase in BMI from baseline, 9.2  1.9% at 6 months;
15.2  2.6% at 12 months). Six subjects at 6 months and 11
subjects at 12 months had recovered weight (10% or greater
increase in BMI), and four subjects at 6 months and eight
subjects at 12 months had recovered weight and menstrual
function. Analysis of rate of change over time (Table 2) dem-
onstrated a significantly greater increase in lean body mass
in AN compared with control such that at 6 and 12 months
lean body mass in AN was no longer different from control.
The AN group had a significant increase in percentage body
fat compared with control. However, percentage body fat
remained lower than control at 6 and 12 months.
There was no difference in linear growth velocity between
AN and control, nor between recovered and nonrecovered
AN over the year (data not shown).
Nutritional intake and activity data
Analysis of calcium and vitamin D intake by either 4-d
food records or diet history was comparable. Therefore, only
intake by food records is reported. Forty-two percent of AN
patients and 50% of controls had a calcium intake less than
the recommended daily allowance (RDA) of calcium (1300
mg/d) at baseline. Both groups also had a high proportion
of subjects with dietary calcium deficiency at follow-up (AN,
38% at 6 months, 33% at 12 months; control, 87% at 6 months,
50% at 12 months). This high degree of dietary calcium de-
ficiency occurred despite a range of supplementation in AN
(28% at baseline, 38% at 6 months, 54% at 12 months) and
control subjects (32% at baseline, 13% at 6 months, 17% at 12
months). In 42% of AN patients and 50% of controls, vitamin
D intake was less than the RDA at baseline, with a high
proportion of subjects (AN, 69% at 6 months, 53% at 12
months; control, 100% at 6 months, 64% at 12 months) con-
tinuing to have dietary deficiency at follow-up. A high rate
of dietary deficiency occurred despite many subjects taking
vitamin D supplements (AN, 42% at baseline, 92% at 6
months, 73% at 12 months; control, 44% at baseline, 33% at
6 months, 50% at 12 months).
Historical assessment of activity level demonstrated that
AN subjects tended to be more physically active than con-
trols at baseline (Table 1), whereas at follow-up there was no
difference between the groups.
Bone density data
Bone density data at each time point and rate of change in
bone density in each group are provided in Table 3. At
baseline, lumbar spine (L1-L4) BMD was significantly lower
in AN subjects and remained significantly reduced at 6- and
12-month follow-up visits. Similar differences in lumbar
bone mineral apparent density, a calculated volumetric den-
sity, were demonstrated using the formula of Katzman et al.
(15). Lumbar BMD was more than 1 sd below the mean of the
controls in 37% of AN subjects at baseline, 57% at 6 months,
and 71% at 12 months. Twenty-four percent of AN subjects
had a lumbar BMD more than 2 sd below the normal mean
at 12 months. The increasing frequency of osteopenia in AN
was due to a significantly greater rate of change in BMD in
controls than in AN. Similarly, the increase in lumbar bone
mineral content (BMC) was significantly greater in control
TABLE 1. Baseline clinical and anthropometric data
AN (n  19) Control (n  19) P value
CA (yr) 15.4  0.4 [12.9–17.8] 14.6  0.4 [12.1–17.8] NS
BA (yr) 15.0  0.4 [12–18] 15.1  0.4 [13–18] NS
BA/CA 0.98  0.01 1.04  0.01 0.003
Height (cm) 162.3  1.4 162.7  1.4 NS
Weight (kg) 43.5  1.7 58.0  1.7 0.0001
Duration of illness (months) 14  3 [1–48]
Amenorrhea
No. premenarchal 6 3
No. primary 1 0
No. secondary 12 0
Duration (months) 21  4 [6–36]
Activity (h/wk) 17.8  2.2 11.9  2.6 0.07
All values are expressed as mean  SEM. Ranges are in brackets. The P value is for comparison between AN and control subjects by t test.
NS, Not significant.
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subjects. The control group had a significantly greater
monthly increase in lumbar BMD of 0.003  0.001
g/cm2month compared with 0.000  0.001 g/cm2month in
the AN group (P  0.04). Change in lumbar BMD was not
different in AN subjects who recovered (n  11) compared
with those who did not recover (n  6) at 12 months, such
that lumbar BMD remained reduced even in subjects who
were weight recovered at 12 months (AN, 0.88 0.03 g/cm2,
vs. control, 0.98  0.03 g/cm2; P  0.02). There were no
recovered subjects whose lumbar BMD z-score increased
from below1 to above1. As illustrated in Fig. 1, those in
the AN group who recovered weight had variable changes
in lumbar BMD over the year, with the rate of change not
significantly different from those without weight recovery.
The percentage change in lumbar BMD in patients who re-
covered weight (2.3% to 9.2%) was similar to those who
recovered menses as well as weight (3.1% to 5.5%). Two
AN subjects who had a decrease in BMI at 12 months had a
decrease of 3.8% and 5.3% in lumbar BMD over the year. All
but one control subject had a positive change of variable
degree (0.1–18.8%) in lumbar BMD over the year. There was
a trend toward greater increase in lumbar BMD over the year
in subjects who had immature skeletal maturation at baseline
(AN, n  8; control, n  7), in both AN (immature, n  8,
2.5  1.6%, vs. mature, n  11, 1.2  1.3%; P  0.09) and
control (immature, n  7, 7.5%  2.1%, vs. mature, n  12,
2.0  1.8%; P  0.07) groups.
TABLE 2. Body composition data in AN and control at each time point and change over time (slope)
Baseline 6 months 12 months Slope change/month P value for slope
BMI (kg/m2)
AN 16.4  0.5a 18.0  0.7 18.9  0.6 0.20  0.04 0.005
Control 22.0  0.5 22.4  0.6 22.2  0.7 0.04  0.04
Lean body mass (kg)
AN 33.6  1.0a 35.7  1.3 37.8  1.1 0.33  0.06 0.04
Control 37.4  1.0 38.5  1.2 38.1  1.2 0.14  0.06
Percentage body fat
AN 17.7  1.4a 20.2  1.9 22.8  1.7 0.41  0.11 0.009
Control 31.7  1.4 30.8  1.7 32.2  1.9 0.03  0.11
Baseline, 6-, and 12-month values are expressed as mean SEM. Slope refers to the rate of change per month. The P value for the slope refers
to the difference in slopes between AN and control subjects. For AN subjects, n  19 at baseline, 14 at 6 months, and 17 at 12 months. For
control subjects, n  19 at baseline, 18 at 6 months, and 14 at 12 months.
a P value  0.05 for comparison between AN and control subjects at baseline by t test.
TABLE 3. Bone density data in AN and control at each time point and rate of change (slope)
Baseline 6 months 12 months Slope change/month P value for slope
Lumbar (L1–4) BMD (g/cm2)
AN 0.89  0.02a 0.88  0.03 0.88  0.02 0.000  0.001 0.04
Control 0.96  0.02 0.98  0.02 0.98  0.03 0.003  0.001
Lumbar (L1–4) BMC (g)
AN 46  2 44  2 47  2 0.05  0.08 0.009
Control 50  2 51  2 52  2 0.37  0.08
Lateral spine BMD (g/cm2)
AN 0.70  0.02a 0.69  0.02 0.70  0.02 0.000  0.001 NS
Control 0.80  0.02 0.81  0.02 0.80  0.02 0.000  0.001
Volumetric lumbar BMD (g/cm3)
AN 0.12  0.00a 0.12  0.00 0.12  0.00 0.0003  0.0001 NS
Control 0.13  0.00 0.14  0.00 0.14  0.00 0.0000  0.0001
Total BMD (g/cm2)
AN 1.00  0.02 0.98  0.02 0.98  0.01 0.0015  0.0008 0.09
Control 1.05  0.02 1.05  0.02 1.05  0.02 0.0006  0.0008
Total BMC (g)
AN 1705  55 1662  57 1720  51 1.6  2.5 0.07
Control 1838  55 1891  50 1903  56 7.2  2.6
Baseline, 6-, and 12-month values are expressed as mean SEM. Slope refers to the rate of change per month. The P value for the slope refers
to the difference in slopes between AN and control subjects. NS, Not significant. For AN subjects, n  19 at baseline, 14 at 6 months, and 17
at 12 months. For control subjects, n  19 at baseline, 18 at 6 months, and 14 at 12 months.
a P value  0.05 for comparison between AN and control subjects at baseline by t test.
FIG. 1. Comparison of initial and final lumbar BMD (LBMD) in non-
recovered AN (A; n 6) and recovered AN (B; n 11). No significant
difference was seen in the mean final BMDs in the two groups.
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There was a trend toward lower total body BMD (TBBMD)
and BMC (TBBMC) in AN at baseline as well as a trend
toward greater increase in TBBMD and TBBMC in controls
compared with AN (Table 3).
In the AN group, change in lean body mass from baseline
to 12 months had the strongest correlation with change in
bone density over 12 months. This relationship was true for
lumbar BMD (r  0.62; P  0.008; Fig. 2), lumbar BMC (r 
0.51; P 0.04), TBBMD (r 0.70; P 0.002), and TBBMC (r
0.81; P  0.0003). In addition, there was a tendency for the
change in lean body mass over the first 6 months to be
correlated with the change in bone density in the following
6 months at the lumbar anteroposterior (r  0.56; P  0.06)
and lateral (r 0.56; P 0.07) spine. Similarly, in the control
group, change in lean body mass over the 12-month study
period had the strongest correlation with change in BMD and
BMC over the same period, including lumbar BMD (r 0.80;
P 0.0006; Fig. 2), lumbar BMC (r 0.71; P 0.004), and total
BMD (r  0.51; P  0.06). Change in lean body mass in the
first 6 months was strongly correlated with change in the
following 6 months in lumbar BMD (r 0.75; P 0.003) and
lumbar BMC (r  0.75; P  0.002).
Biochemical data
TSH, serum-ionized calcium, and phosphorus were nor-
mal in all subjects at all time points studied. Hormonal data
at baseline are analyzed on the basis of maturational stage
(immature, BA 15 yr; mature, BA 15 yr) and summarized
in Table 4. Baseline IGF-I levels were significantly reduced in
both immature and mature AN compared with control, with
the most marked reduction in the mature group to less than
50% of control levels. Analysis of rate of change over time
demonstrated that the AN group had a significantly greater
increase in IGF-I compared with control (AN, 8  2 g/
litermonth, vs. control, 4  2 g/litermonth; P  0.0008),
such that at 6 and 12 months, IGF-I levels were not different
from control in the immature group (data not shown). How-
ever, in the mature group, despite significant increases in
IGF-I, levels remained reduced at 6 and 12 months (AN,
300  47 g/liter, vs. control, 499  36 g/liter; and AN,
356 42g/liter, vs. control, 522 45g/liter, respectively).
In recovered subjects at 12 months, IGF-I levels did not differ
from those in nonrecovered subjects. In both AN and control
groups, change in IGF-I over 12 months was strongly cor-
related with change in nutritional markers over 12 months,
including BMI (AN, r 0.76; P 0.001; and control, r 0.71;
P  0.004) and leptin (AN, r  0.66; P  0.009; and control,
r  0.55; P  0.03). There were no differences in IGFBP-3
levels between the groups at any time point studied.
Serum E2 levels at baseline were significantly reduced in
the immature AN group compared with follicular phase
control levels, but not different in the mature group (Table
4). At follow-up, there were no differences in serum E2 levels
in either maturational group. There was a trend toward a
greater increase in serum E2 levels over time in the AN
compared with the control group (AN, 2.8  1.1 pmol/
litermonth, vs. control, 0.1 0.9 pmol/litermonth; P 0.08).
Change in E2 over the first 6 months of observation in the AN
group was correlated with change in BMI (r 0.76; P 0.004)
and percentage body fat (r  0.65; P  0.02). These corre-
lations were not present in the control group. There was no
difference in the rate of change in E2 levels in recovered vs.
nonrecovered AN.
Free T levels at baseline were significantly reduced in the
mature AN group, but not in the immature group (Table 4).
Analysis of rate of change over time demonstrated a signif-
icantly greater increase in free T in the AN compared with
the control group (AN, 0.07  0.03 pmol/litermonth, vs.
control, 0.1  0.7 pmol/litermonth; P  0.02). DHEAS
levels were not different between AN and control in either
maturational group at any time point studied.
Bone turnover markers at baseline are summarized in Ta-
ble 4. In both immature and mature AN groups, baseline
levels of OC, BSAP, DPD, and NTX were significantly re-
duced compared with control levels. At follow-up, bone
turnover markers in the AN group increased, whereas they
decreased in controls, resulting in a markedly different
change in marker levels between the groups over the 12-
month period (OC: AN, 0.9 0.4 g/litermonth, vs. control,
1.1  0.4 g/litermonth, P  0.0007; BSAP: AN, 0.6  0.5
U/litermonth, vs. control, 1.5  0.4 U/litermonth, P 
0.002; DPD: AN, 0.1 0.1 nmol/mmol crmonth, vs. control,
0.4  0.1 nmol/mmol crmonth, P  0.005; and NTX: AN,
4  4 nmol BCE/mmol crmonth, vs. control, 9  4 nmol
FIG. 2. Correlation between change in lean body mass (dLBM) and change in lumbar BMD (dLBMD) over 1 yr in adolescents with AN (A) and
healthy controls (B).
Soyka et al. • Bone Mineral Accrual in Anorexia J Clin Endocrinol Metab, September 2002, 87(9):4177–4185 4181
BCE/mmol crmonth, P 0.01). In the immature AN group,
there were persistent reductions in OC (AN, 60.3  17.0
g/liter, vs. control, 112.0 15.0 g/liter), DPD (AN, 12.9
2.7 nmol/mmol cr, vs. control, 21.3 3.0 nmol/mmol cr) and
NTX (AN, 154  56 nmol BCE/mmol cr, vs. control, 494 
61 nmol BCE/mmol cr) compared with control at 6 months.
There were no differences between the immature AN and
control groups at 12 months. In the mature group, OC at 6
months (AN, 31.8  5.5 g/liter, vs. control, 50.4  4.2
g/liter) was the only reduced marker of bone turnover in
AN at follow-up.
There were significantly greater changes in bone forma-
tion markers in AN subjects who recovered compared with
those who did not, as determined by BSAP and OC (Fig. 3).
In AN subjects, change in lean body mass over the year
was strongly correlated with change in bone turnover over
the year, as assessed by BSAP (r  0.61; P  0.02), NTX (r 
0.62; P  0.02), DPD (r  0.55; P  0.04), and OC (r  0.48;
P  0.08). In addition, change in IGF-I levels over the year
was highly correlated with change in bone turnover over the
same period, as measured by OC (r  0.77; P  0.001) and
DPD (r  0.66; P  0.01). In addition, there was a trend
toward correlation with BSAP (r 0.47; P 0.09). There was
also a strong correlation between change in free T and change
in bone formation markers OC (r 0.58; P 0.03) and BSAP
(r 0.53; P 0.05) over the year in the AN group. There were
no such correlations in the control group between bone turn-
over and lean body mass, IGF-I, or free T levels. There was
no correlation between change in E2 levels and bone turnover
markers in either group.
In the AN group, an increase in specific bone turnover
markers was predictive of an increase in bone mineral. Over
the year, increased NTX was correlated with an improve-
ment in all bone mineral measures over the same period,
including lumbar BMC (r  0.58; P  0.03), and BMD (r 
0.53; P  0.05), lateral spine BMD (r  0.58; P  0.04), and
total BMC (r 0.69; P 0.006) and BMD (r 0.69; P 0.006).
An increase in NTX for the first 6 months tended to predict
a rise in lumbar BMC (r 0.55; P 0.06) and BMD (r 0.51;
P  0.09) for the subsequent 6 months. In addition, an in-
crease in BSAP in the first 6 months was correlated with a rise
in lumbar BMC during the following 6 months (r 0.70; P
0.02).
Discussion
We prospectively investigated changes in bone density
and bone metabolism markers over 1 yr in adolescent girls
with AN compared with healthy adolescents of comparable
skeletal maturation. Our data indicates that despite improve-
ment in nutritional status and recovery of menstrual func-
tion, girls with AN had reduced bone mineral accrual and
progressive spinal osteopenia over the year compared with
their healthy counterparts. Change in lean body mass was the
most significant determinant of change in lumbar BMD in
both AN and healthy girls. At the end of the 12-month study
period, none of the AN subjects had an improvement in
lumbar BMD z-score from below 1 to above 1, and 24%
of AN subjects had a lumbar BMD more than 2 sd below the
mean of the healthy girls. However, the low levels of bone
FIG. 3. Percentage change in markers of bone
formation (left) and bone resorption (right) over
1 yr. Percentage changes in levels of OC and
BSAP were significantly higher in recovered AN
than in nonrecovered AN (P  0.03 for OC; P 
0.0007 for BSAP) and controls (P  0.0003 for
OC; P  0.0001 for BSAP). Percentage changes
in levels of markers of bone resorption (DPD and
NTX) were significantly higher in recovered AN
than in controls (P 0.02 for DPD; P 0.002 for
NTX). *, Significantly different from healthy
controls; **, significantly different from recov-
ered AN.










IGF-I (g/liter) 390  50a 587  54 251  37a 566  35
IGFBP-3 (g/liter) 4564  258 4920  276 4040  229 4533  219
E2 (pmol/liter) 53.6  5.5
a 77.5  6.6 63.9  7.7 73.8  7.0
Free T (pmol/liter) 6.8  0.8 6.7  0.8 5.7  0.9a 8.6  0.9
DHEAS (mol/liter) 3.5  0.5 3.4  0.5 4.9  0.8 6.0  0.8
Leptin (g/liter) 3.7  1.4a 10.3  1.5 2.4  1.4a 13.9  1.4
OC (g/liter) 59.6  9.6a 109.3  10.3 33.9  6.1a 55.8  5.9
BSAP (U/liter) 48.1  13.6a 108.7  14.5 21.0  3.5a 32.9  3.4
DPD (nmol/mmol cr) 12.8  2.4a 23.2  2.5 8.2  1.4a 13.4  1.4
NTX (nmol BCE/mmol cr) 175  112 517  120 86  17a 142  16.4
Baseline hormone and bone turnover marker data in immature (BA  15 yr) and mature (BA  15 yr) subjects. Values are expressed as
mean  SEM.
aP value  0.05 for comparison between AN and control in each group by t test.
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turnover markers present in girls with AN at baseline sig-
nificantly increased in association with improvement in nu-
tritional status, specifically an increase in lean body mass and
the nutritionally dependent bone growth factor IGF-I. In
addition, we found that the rise in the surrogate marker of
bone resorption NTX over the year was correlated with im-
provement in lumbar and total BMC and BMD in the AN
group. Moreover, our data suggests that an increase in the
bone turnover markers NTX and BSAP in AN over time may
be predictive of an increase in lumbar BMC and BMD.
The onset of AN frequently occurs during adolescence
when maximal bone mineral accrual takes place, thereby
making adolescent girls at high risk for reduced peak bone
mass. Cross-sectional studies have shown that approxi-
mately half of adolescent girls with AN have low BMD in-
volving trabecular and cortical bone (1–4). However, there is
little prospective data available regarding the progression of
osteopenia. In a prospective study of adolescent girls with
AN by Bachrach et al. (2), spinal BMD was assessed by dual-
photon absorptiometry in 15 girls over 12–16 months. In
these girls, mean lumbar BMD was unchanged, but the
change among patients varied considerably with weight loss
or gain (13.9% to 30.3%, respectively). In addition, one third
of females examined retrospectively who had recovered
from AN during adolescence had persistent osteopenia (2).
Biller et al. (8) found that women with AN who had disease
onset during adolescence had lower spinal bone density
compared with those with disease onset in adulthood. The
majority of published data in adolescents with AN is not
prospective, and therefore little is known about bone mineral
accrual during this critical period. Specifically, because
height and bone maturation significantly impact BMD mea-
surements and there is little available regarding normal pro-
spective data on changes in BMD in adolescents, comparison
of AN with healthy adolescents of similar stature and bone
maturation is critical. To date, no such studies have been
performed. Our data are in agreement with Bachrach et al. (2)
in that our two subjects who lost weight did have evidence
of bone loss, with a decrease in lumbar BMD of 3.8 and 
5.9% after 1 yr. However, we found that healthy girls had
greater gains in bone mineral than girls with AN, even
among weight recovered subjects, suggesting that poor bone
mineral accrual contributes to osteopenia in girls with AN.
Moreover, no recovered subjects had an improvement in
spinal BMD z-score from below 1 to greater than 1, in-
dicating that there was no catch-up in bone mineral accretion
with recovery over the study period.
In healthy females, bone mass increases throughout child-
hood with maximal bone mass accrual occurring in early to
mid puberty, and slowing in late puberty (16–19). Longitu-
dinal data from healthy girls demonstrate that gain in bone
mass is most pronounced between 11 and 14 yr of age, and
falls significantly after 16 yr of age and/or 2 yr after men-
arche (19). Therefore, it would be expected that bone mineral
accrual in girls with AN would differ depending on the
maturational stage. Because Tanner breast staging is difficult
in girls with AN who are hypoestrogenemic, we classified
girls as immature or mature based on skeletal maturation,
which is a more objective measure. As expected, bone min-
eral accrual differed in each group by maturational stage,
with the immature girls tending to have greater gains in bone
mineral over the year than the mature girls. In addition, mean
changes in BMD in immature AN indicate low bone mineral
accrual, whereas changes in the mature group indicate bone
loss. These data indicate that the pathogenesis of osteopenia
in AN may differ depending on maturational stage.
The determinants of change in BMD in adolescents with
AN have not been extensively examined. We and others have
shown that body mass, particularly lean tissue, is a major
determinant of BMD in healthy children and adolescents (3,
20). Estrogen has been proposed as a contributing factor to
the low bone density in AN because primary or secondary
amenorrhea is a nearly universal feature. In adolescents,
lower lumbar bone density is seen in amenorrheic teens
compared with those with normal menses but is not signif-
icant when patients are controlled for body weight (21–22).
Bachrach et al. (2) found a significant correlation between
change in BMI and change in lumbar BMD in adolescent girls
with AN with weight recovery, even before resumption of
menses. We did not find a correlation between bone density
in AN and menstrual status, E2 levels, or duration of amen-
orrhea. Our data indicate that lean body mass specifically
was a major determinant of change in total and lumbar BMD
in girls with AN, as well as healthy controls. Moreover,
change in lean body mass over the first 6 months of study was
predictive of change in lumbar BMD over the subsequent 6
months, indicating that an improvement in lean body mass
may predict an increase in spinal bone density in AN. Girls
with a significant change in estrogen status, as demonstrated
by resumption of menses, did not have greater gains in BMD
compared with girls who gained weight only. In addition,
change in E2 levels over the study period did not correlate
with change in BMD or bone turnover markers. These data
indicate that change in nutritional status is an important
predictor of change in BMD, independent of estrogen status.
It is likely that not all girls who resumed menses were having
ovulatory cycles, although this was not tested. Whether or
not prolonged suppression of bone mineral accrual was re-
lated to lack of resumption of ovulatory menstrual cycles is
not known.
Change in BMD is a slow process, and the impact of
recovery on BMD may not be apparent over a relatively short
time frame. Examination of indirect measures of bone turn-
over provides a more immediate view of bone mineral status
to study the impact of weight and gonadal recovery on bone.
It is important to note that in normal adolescents, both bone
formation and resorption markers are at very high levels
(23–25) due to rapid bone growth, mineralization, and re-
modeling, in contrast to relatively low levels of turnover
markers in adulthood during which time only remodeling
occurs. Bone turnover decreases toward adult levels during
late puberty (23–25). The abnormalities in bone metabolism
in adolescents with AN and their long-term impact are not
completely understood. We were the first to describe low
bone formation in mature adolescent girls with AN com-
pared with CA- and BA-matched controls (3). In this report,
we demonstrate that low bone turnover also occurs in im-
mature girls with AN. To date, there are no published pro-
spective data on bone turnover in adolescents with AN dur-
ing recovery compared with healthy girls of similar
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maturational stage. In contrast to no change in mean spinal
BMD in AN subjects at 12 months, there were major changes
in bone turnover in association with nutritional recovery. AN
subjects, who had a mean 15.2% increase in BMI over the
year, had significantly greater increase in OC, BSAP, DPD,
and NTX compared with controls, such that by 12 months
bone turnover was no longer different between the groups.
These data suggest that bone turnover in subjects with AN
undergoing nutritional recovery increases from abnormally
suppressed levels to levels equivalent to that of healthy con-
trol girls. In contrast, levels of bone turnover markers in the
healthy girls decreased as expected as they continued
through puberty.
When assessing bone metabolism in growing children,
levels of bone turnover markers may reflect changes in min-
eralization, changes in growth of bones, or both. Examination
of the correlation between bone turnover markers and mea-
surements of bone size and density by computed tomogra-
phy in children found that bone resorption markers corre-
lated negatively with bone size and volume, whereas bone
formation markers correlated negatively with true bone den-
sity; however, these data are not prospective (26). These
observations are consistent with the known decrease in bone
turnover markers that occurs in late puberty with consoli-
dation of bone density and completion of bone growth. Our
interpretation of the prospective changes in bone turnover
markers in our subjects is that they most likely reflect
changes in bone mineralization rather than growth, because
there were no significant differences in lumbar bone area,
linear growth, or height between the groups.
Increases in bone turnover markers occurred even without
recovery from AN, but increases in bone formation were
greater in those AN subjects who increased BMI by 10% or
more compared with those who did not. Changes in lean
body mass and IGF-I levels were the strongest correlates of
change in bone turnover in AN over the year of study. We
have previously reported a strong correlation between IGF-I,
an important bone trophic factor, and markers of bone for-
mation, OC and BSAP, in adolescent girls with AN (3). As
noted above, in this study we show that change in IGF-I is
also strongly correlated with longitudinal changes in bone
formation and resorption. Both markers of bone formation
and resorption increased in association with a rise in IGF-I,
similar to that reported in studies of adult patient popula-
tions under IGF-I administration (27–29), including adult
women with AN (30). The increase in markers of bone re-
sorption may relate to IGF-I indirectly activating osteoclast
activity through stimulation of osteoblasts, as suggested by
in vitro study (31). The normalization of suppressed bone
turnover seen in our AN subjects is similar to that demon-
strated in GH-deficient children under recombinant human
GH therapy (32–33).
Reduced levels of androgens may potentially contribute to
the low bone density seen in AN. Serum free T levels were
significantly reduced at baseline in the mature AN group
only, whereas serum DHEAS did not differ between the
groups at either maturational stage, suggesting a relatively
greater deficiency in gonadal vs. adrenal androgens in ma-
ture AN. These data may reflect increased androgen secre-
tion from the ovaries in more mature healthy girls. Changes
in levels of free T in AN were correlated with change in bone
formation markers over the year, suggesting that free T has
an anabolic role in bone metabolism in adolescents with AN,
as has been reported in normal adult women (34).
Of particular significance is that an increase in specific
bone turnover markers was predictive of an increase in BMD
in the AN group. An increase in BSAP in the first 6 months
was correlated with a rise in lumbar BMC during the fol-
lowing 6 months. In addition, there was a trend toward an
increase in NTX for the first 6 months to predict a rise in
lumbar BMC and BMD for the subsequent 6 months in AN
subjects. Over the year, an increase in NTX correlated with
an improvement in all bone density measures over the same
period, including lumbar BMC and BMD, lateral spine BMD,
TBBMC, and TBBMD in the AN group. These data indicate
that bone metabolism in AN normalizes over the course of
1 yr with nutritional recovery, and a rise in specific bone
turnover markers from a previously suppressed state may be
an indicator of recovery of bone mineral accrual.
Potentially important environmental factors for preserva-
tion of bone health include exercise and calcium intake, nei-
ther of which correlated with bone density or bone turnover
in our subjects. However, a large proportion of both AN and
healthy subjects were found to have dietary calcium and
vitamin D deficiency, during a time when skeletal needs for
calcium are greatest (35), and despite supplementation in
many subjects. Although the study participants were not
instructed to take supplements, they were educated about
the importance of calcium for bone health as well as the RDA
for calcium and vitamin D for adolescents at each visit. There
was no improvement in intake of these nutrients during the
study in either group. Our data support the findings of other
studies in which a majority of adolescent girls are found to
be deficient in dietary calcium intake (36, 37) and suggest that
many girls may require concentrated efforts at education and
dietary supplementation to meet skeletal needs during
adolescence.
Our data demonstrate that osteopenia may persist in ad-
olescent girls with AN despite recovery over 1 yr and that,
in contrast to bone loss in adults with AN, poor bone mineral
accrual is a critical component of the osteopenia seen in this
population. These are the first data to demonstrate normal-
ization of bone turnover markers in adolescents recovering
from AN, in association with an increase in lean body mass
and the nutritionally dependent bone trophic hormone IGF-I.
The rise in bone turnover markers may be an early indicator
of an increase in BMD in girls with AN undergoing nutri-
tional recovery. Further investigation is required to deter-
mine whether ongoing recovery will lead to an improvement
in BMD in this population.
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